Daily administration of DAPA mitigated OVX/ d-Gal-induced elevation in AD hallmarks to 31% (BACE1; P < 0.0001) and 41% (p-Tau; P < 0.0001). The gene discussed is MAPT; the disease is Alzheimer disease.